Amag Pharmaceuticals (AMAG) Stock Price, Quote, News and Overview
NASDAQ:AMAG - Nasdaq -
AMAG Quote, Performance and Key Statistics
13.75
+0.02 (+0.15%)
The current stock price of AMAG is 13.75 null. In the past month the price increased by 0.88%. In the past year, price increased by 39.45%.
About AMAG
Company Profile
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex', the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
Company Info
Amag Pharmaceuticals
1100 WINTER STREET
WALTHAM MA 02451
CEO: William K. Heiden
Phone: 617-498-3300
Amag Pharmaceuticals / AMAG FAQ
What is the stock price of Amag Pharmaceuticals today?
The current stock price of AMAG is 13.75 null. The price increased by 0.15% in the last trading session.
What is the ticker symbol for Amag Pharmaceuticals stock?
The exchange symbol of Amag Pharmaceuticals is AMAG and it is listed on the Nasdaq exchange.
On which exchange is AMAG stock listed?
AMAG stock is listed on the Nasdaq exchange.
What is Amag Pharmaceuticals worth?
Amag Pharmaceuticals (AMAG) has a market capitalization of 477.47M null. This makes AMAG a Small Cap stock.
What are the support and resistance levels for Amag Pharmaceuticals (AMAG) stock?
Amag Pharmaceuticals (AMAG) has a support level at 13.74 and a resistance level at 13.76. Check the full technical report for a detailed analysis of AMAG support and resistance levels.
Should I buy Amag Pharmaceuticals (AMAG) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AMAG, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AMAG, evaluating the profitability, health, valuation and growth aspects
- Amag Pharmaceuticals (AMAG) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Amag Pharmaceuticals (AMAG) Sales and EPS estimates to see what analysts future expectations are.
- Amag Pharmaceuticals (AMAG) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Amag Pharmaceuticals (AMAG) Insider and Institutional Ownership to learn about the owners and their transactions.
- Amag Pharmaceuticals (AMAG) Stock Chart to make your own analysis
- Amag Pharmaceuticals (AMAG) Latest news and press-releases to stay up to date.
Does Amag Pharmaceuticals (AMAG) stock pay dividends?
AMAG does not pay a dividend.
What is the Price/Earnings (PE) ratio of Amag Pharmaceuticals (AMAG)?
Amag Pharmaceuticals (AMAG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.3).
AMAG Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AMAG. When comparing the yearly performance of all stocks, AMAG is one of the better performing stocks in the market, outperforming 88.08% of all stocks.
AMAG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AMAG. Both the profitability and financial health of AMAG have multiple concerns.
AMAG Financial Highlights
Over the last trailing twelve months AMAG reported a non-GAAP Earnings per Share(EPS) of -2.3. The EPS increased by 61.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -74.73% | ||
| ROA | -31% | ||
| ROE | N/A | ||
| Debt/Equity | 0.08 |
AMAG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 60% to AMAG. The Buy consensus is the average rating of analysts ratings from 7 analysts.